Baldwin Wealth Partners LLC MA Has $4.56 Million Stake in Novartis AG $NVS

Key Points

• Baldwin Wealth Partners LLC MA reduced its stake in Novartis AG by 9.1%, owning 37,644 shares worth approximately $4.56 million after selling 3,776 shares.
• Novartis' latest earnings report showed $2.42 earnings per share, exceeding expectations and reflecting a 12.3% year-over-year revenue growth to $14.05 billion.
• The company has a market capitalization of $276.81 billion and a current consensus rating of "Hold" from analysts, with a target price of $120.33.

Baldwin Wealth Partners LLC MA decreased its position in shares of Novartis AG (NYSE:NVS - Free Report) by 9.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,644 shares of the company's stock after selling 3,776 shares during the period. Baldwin Wealth Partners LLC MA's holdings in Novartis were worth $4,555,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVS. Essex Savings Bank raised its position in shares of Novartis by 1.9% during the second quarter. Essex Savings Bank now owns 4,611 shares of the company's stock valued at $558,000 after buying an additional 85 shares during the last quarter. Physician Wealth Advisors Inc. raised its position in shares of Novartis by 5.8% during the second quarter. Physician Wealth Advisors Inc. now owns 1,541 shares of the company's stock valued at $186,000 after buying an additional 85 shares during the last quarter. Gallacher Capital Management LLC increased its stake in Novartis by 1.7% in the second quarter. Gallacher Capital Management LLC now owns 5,371 shares of the company's stock valued at $650,000 after acquiring an additional 92 shares during the period. Ascent Group LLC increased its stake in Novartis by 0.7% in the second quarter. Ascent Group LLC now owns 14,121 shares of the company's stock valued at $1,709,000 after acquiring an additional 97 shares during the period. Finally, Sage Rhino Capital LLC increased its stake in Novartis by 1.2% in the second quarter. Sage Rhino Capital LLC now owns 8,120 shares of the company's stock valued at $983,000 after acquiring an additional 99 shares during the period. Institutional investors and hedge funds own 13.12% of the company's stock.

Novartis Stock Performance

NVS stock opened at $131.04 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.82 and a quick ratio of 0.62. The company has a 50 day moving average price of $124.85 and a 200 day moving average price of $117.72. Novartis AG has a fifty-two week low of $96.06 and a fifty-two week high of $133.55. The stock has a market capitalization of $276.81 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 1.83 and a beta of 0.64.

Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings data on Thursday, July 17th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. Novartis had a net margin of 25.64% and a return on equity of 41.08%. The firm had revenue of $14.05 billion during the quarter, compared to analysts' expectations of $13.94 billion. During the same quarter in the previous year, the company posted $1.97 EPS. Novartis's revenue was up 12.3% on a year-over-year basis. Analysts forecast that Novartis AG will post 8.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVS. The Goldman Sachs Group reissued a "sell" rating and issued a $118.00 target price (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. Wall Street Zen cut shares of Novartis from a "strong-buy" rating to a "buy" rating in a research note on Friday, August 22nd. Morgan Stanley raised shares of Novartis from an "underweight" rating to an "equal weight" rating and set a $123.00 target price on the stock in a research note on Friday, August 8th. Weiss Ratings reissued a "buy (b)" rating on shares of Novartis in a research note on Wednesday. Finally, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Novartis in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Novartis currently has a consensus rating of "Hold" and a consensus target price of $120.33.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.